- Home
- RDI vs KPTI Comparison
RDI vs KPTI Comparison
Compare RDI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- KPTI
- Stock Information
- Founded
- RDI 1937
- KPTI 2008
- Country
- RDI United States
- KPTI United States
- Employees
- RDI N/A
- KPTI N/A
- Industry
- RDI Movies/Entertainment
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- KPTI Health Care
- Exchange
- RDI Nasdaq
- KPTI Nasdaq
- Market Cap
- RDI 30.1M
- KPTI 33.6M
- IPO Year
- RDI N/A
- KPTI 2013
- Fundamental
- Price
- RDI $1.25
- KPTI $4.95
- Analyst Decision
- RDI Hold
- KPTI Strong Buy
- Analyst Count
- RDI 1
- KPTI 5
- Target Price
- RDI $2.40
- KPTI $61.00
- AVG Volume (30 Days)
- RDI 42.0K
- KPTI 161.4K
- Earning Date
- RDI 05-14-2025
- KPTI 05-07-2025
- Dividend Yield
- RDI N/A
- KPTI N/A
- EPS Growth
- RDI N/A
- KPTI N/A
- EPS
- RDI N/A
- KPTI N/A
- Revenue
- RDI $210,527,000.00
- KPTI $145,237,000.00
- Revenue This Year
- RDI $11.97
- KPTI $4.87
- Revenue Next Year
- RDI $6.40
- KPTI $16.29
- P/E Ratio
- RDI N/A
- KPTI N/A
- Revenue Growth
- RDI N/A
- KPTI N/A
- 52 Week Low
- RDI $1.17
- KPTI $3.51
- 52 Week High
- RDI $1.89
- KPTI $21.30
- Technical
- Relative Strength Index (RSI)
- RDI 45.11
- KPTI 48.29
- Support Level
- RDI $1.18
- KPTI $3.83
- Resistance Level
- RDI $1.28
- KPTI $4.36
- Average True Range (ATR)
- RDI 0.08
- KPTI 0.43
- MACD
- RDI 0.00
- KPTI 0.22
- Stochastic Oscillator
- RDI 25.00
- KPTI 91.72
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.